Cargando…

Precautions for Patients Taking Aromatase Inhibitors

Aromatase inhibitors are the drug of choice for the treatment of estrogen receptor– or progesterone receptor–positive breast cancer in postmenopausal women. Aromatase is an enzyme that catalyzes the final and rate-limiting step in the biosynthesis of estrogen. Inhibitors of this enzyme are an effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Heery, Mary, Farley, Stephen, Sparkman, Rhett, Healy, John, Eighmy, William, Zahrah, George, Zelkowitz, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848814/
https://www.ncbi.nlm.nih.gov/pubmed/33532117
http://dx.doi.org/10.6004/jadpro.2020.11.2.6
_version_ 1783645206051028992
author Heery, Mary
Farley, Stephen
Sparkman, Rhett
Healy, John
Eighmy, William
Zahrah, George
Zelkowitz, Richard
author_facet Heery, Mary
Farley, Stephen
Sparkman, Rhett
Healy, John
Eighmy, William
Zahrah, George
Zelkowitz, Richard
author_sort Heery, Mary
collection PubMed
description Aromatase inhibitors are the drug of choice for the treatment of estrogen receptor– or progesterone receptor–positive breast cancer in postmenopausal women. Aromatase is an enzyme that catalyzes the final and rate-limiting step in the biosynthesis of estrogen. Inhibitors of this enzyme are an effective therapy for breast cancer. The benefits of these agents have been clearly shown through various clinical trials, yet adherence may be challenging for some patients due to issues of drug interactions, proper first dose education, and adverse effects. Education to prevent and treat adverse effects is of the utmost importance to promote adherence.
format Online
Article
Text
id pubmed-7848814
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-78488142021-02-01 Precautions for Patients Taking Aromatase Inhibitors Heery, Mary Farley, Stephen Sparkman, Rhett Healy, John Eighmy, William Zahrah, George Zelkowitz, Richard J Adv Pract Oncol Practice Matters Aromatase inhibitors are the drug of choice for the treatment of estrogen receptor– or progesterone receptor–positive breast cancer in postmenopausal women. Aromatase is an enzyme that catalyzes the final and rate-limiting step in the biosynthesis of estrogen. Inhibitors of this enzyme are an effective therapy for breast cancer. The benefits of these agents have been clearly shown through various clinical trials, yet adherence may be challenging for some patients due to issues of drug interactions, proper first dose education, and adverse effects. Education to prevent and treat adverse effects is of the utmost importance to promote adherence. Harborside Press LLC 2020-03 2020-03-01 /pmc/articles/PMC7848814/ /pubmed/33532117 http://dx.doi.org/10.6004/jadpro.2020.11.2.6 Text en © 2020 Harborside™ http://creativecommons.org/licenses/by-nc-nd/3.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Practice Matters
Heery, Mary
Farley, Stephen
Sparkman, Rhett
Healy, John
Eighmy, William
Zahrah, George
Zelkowitz, Richard
Precautions for Patients Taking Aromatase Inhibitors
title Precautions for Patients Taking Aromatase Inhibitors
title_full Precautions for Patients Taking Aromatase Inhibitors
title_fullStr Precautions for Patients Taking Aromatase Inhibitors
title_full_unstemmed Precautions for Patients Taking Aromatase Inhibitors
title_short Precautions for Patients Taking Aromatase Inhibitors
title_sort precautions for patients taking aromatase inhibitors
topic Practice Matters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848814/
https://www.ncbi.nlm.nih.gov/pubmed/33532117
http://dx.doi.org/10.6004/jadpro.2020.11.2.6
work_keys_str_mv AT heerymary precautionsforpatientstakingaromataseinhibitors
AT farleystephen precautionsforpatientstakingaromataseinhibitors
AT sparkmanrhett precautionsforpatientstakingaromataseinhibitors
AT healyjohn precautionsforpatientstakingaromataseinhibitors
AT eighmywilliam precautionsforpatientstakingaromataseinhibitors
AT zahrahgeorge precautionsforpatientstakingaromataseinhibitors
AT zelkowitzrichard precautionsforpatientstakingaromataseinhibitors